These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 21489821)
1. Pathological features of in-stent restenosis after sirolimus-eluting stent versus bare metal stent placement. Abe S; Yoneda S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T Cardiovasc Pathol; 2012; 21(2):e19-22. PubMed ID: 21489821 [TBL] [Abstract][Full Text] [Related]
2. The wound healing response after implantation of a drug-eluting stent is impaired persistently in the long term. Nasuno T; Tokura M; Kageyama M; Toyoda S; Sakuma M; Komatsu T; Taguchi I; Abe S; Inoue T Heart Vessels; 2016 Jun; 31(6):985-9. PubMed ID: 25939630 [TBL] [Abstract][Full Text] [Related]
3. Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation. Yoneda S; Abe S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T Coron Artery Dis; 2013 Aug; 24(5):368-73. PubMed ID: 23744617 [TBL] [Abstract][Full Text] [Related]
4. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471 [TBL] [Abstract][Full Text] [Related]
5. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions. Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862 [TBL] [Abstract][Full Text] [Related]
6. Differences in tissue characterization of restenotic neointima between sirolimus-eluting stent and bare-metal stent: integrated backscatter intravascular ultrasound analysis for in-stent restenosis. Ando H; Amano T; Takashima H; Harada K; Kitagawa K; Suzuki A; Kunimura A; Shimbo Y; Harada K; Yoshida T; Kato B; Uetani T; Kato M; Matsubara T; Kumagai S; Yoshikawa D; Isobe S; Ishii H; Murohara T Eur Heart J Cardiovasc Imaging; 2013 Oct; 14(10):996-1001. PubMed ID: 23341147 [TBL] [Abstract][Full Text] [Related]
7. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis. Habara S; Mitsudo K; Goto T; Kadota K; Fujii S; Yamamoto H; Kato H; Takenaka S; Fuku Y; Hosogi S; Hirono A; Yamamoto K; Tanaka H; Hasegawa D; Nakamura Y; Tasaka H; Otsuru S; Okamoto Y; Yamada C; Miyamoto M; Inoue K Heart; 2008 Sep; 94(9):1162-5. PubMed ID: 18032460 [TBL] [Abstract][Full Text] [Related]
8. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. van Beusekom HM; Saia F; Zindler JD; Lemos PA; Swager-Ten Hoor SL; van Leeuwen MA; de Feijter PJ; Serruys PW; van der Giessen WJ Eur Heart J; 2007 Apr; 28(8):974-9. PubMed ID: 17434882 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of early inflammatory response after sirolimus-eluting stent vs bare metal stent implantation in native coronary lesions. Li JJ; Qin XW; Yang XC; Li ZC; Zeng HS; Xu B; Gao Z; Wu YJ; Zhang X; Zhang CY Clin Chim Acta; 2008 Oct; 396(1-2):38-42. PubMed ID: 18634770 [TBL] [Abstract][Full Text] [Related]
10. Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world. Fineschi M; Gori T; Pierli C; Casini S; Sinicropi G; Buti A; Del Pasqua A; Bravi A Can J Cardiol; 2005 Dec; 21(14):1281-5. PubMed ID: 16341297 [TBL] [Abstract][Full Text] [Related]
11. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178 [TBL] [Abstract][Full Text] [Related]
12. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953 [TBL] [Abstract][Full Text] [Related]
14. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. Kotani J; Awata M; Nanto S; Uematsu M; Oshima F; Minamiguchi H; Mintz GS; Nagata S J Am Coll Cardiol; 2006 May; 47(10):2108-11. PubMed ID: 16697331 [TBL] [Abstract][Full Text] [Related]
15. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023 [TBL] [Abstract][Full Text] [Related]
16. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Tada N; Virmani R; Grant G; Bartlett L; Black A; Clavijo C; Christians U; Betts R; Savage D; Su SH; Shulze J; Kar S Circ Cardiovasc Interv; 2010 Apr; 3(2):174-83. PubMed ID: 20407114 [TBL] [Abstract][Full Text] [Related]
17. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663 [TBL] [Abstract][Full Text] [Related]
18. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention. Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a sirolimus-eluting stent (Cypher) for diffuse in-stent restenosis inside a bare metal stent. Sakamoto H; Ishikawa T; Mutoh M; Okada H; Tsurusaki T; Ohta M; Higashitani M; Nakano Y; Fuda Y; Imai K; Horie T; Mochizuki S Int Heart J; 2006 Sep; 47(5):651-61. PubMed ID: 17106136 [TBL] [Abstract][Full Text] [Related]
20. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]